PH12021552133A1 - Aromatic derivatives, preparation methods, and medical uses thereof - Google Patents
Aromatic derivatives, preparation methods, and medical uses thereofInfo
- Publication number
- PH12021552133A1 PH12021552133A1 PH1/2021/552133A PH12021552133A PH12021552133A1 PH 12021552133 A1 PH12021552133 A1 PH 12021552133A1 PH 12021552133 A PH12021552133 A PH 12021552133A PH 12021552133 A1 PH12021552133 A1 PH 12021552133A1
- Authority
- PH
- Philippines
- Prior art keywords
- aromatic derivatives
- preparation methods
- medical uses
- present disclosure
- fgfr4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2019/076926 WO2020177067A1 (en) | 2019-03-05 | 2019-03-05 | Aromatic derivatives, preparation methods, and medical uses thereof |
| PCT/CN2020/075849 WO2020177534A1 (en) | 2019-03-05 | 2020-02-19 | Aromatic derivatives, preparation methods, and medical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021552133A1 true PH12021552133A1 (en) | 2022-08-22 |
Family
ID=72337401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2021/552133A PH12021552133A1 (en) | 2019-03-05 | 2020-02-19 | Aromatic derivatives, preparation methods, and medical uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11976058B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3935048A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7470708B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210135558A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111902400B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3132405A1 (cg-RX-API-DMAC7.html) |
| PH (1) | PH12021552133A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202109522VA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI860334B (cg-RX-API-DMAC7.html) |
| WO (2) | WO2020177067A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12595370B2 (en) | 2018-03-02 | 2026-04-07 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
| US10935695B2 (en) | 2018-03-02 | 2021-03-02 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
| US12595371B2 (en) | 2018-03-02 | 2026-04-07 | Johnson & Johnson Vision Care, Inc. | Contact lens with improved vision break-up time |
| US12674032B2 (en) | 2019-06-28 | 2026-07-07 | Johnson & Johnson Vision Care, Inc. | Polymerizable fused tricyclic compounds as absorbers of UV and visible light |
| US20220194944A1 (en) * | 2020-12-18 | 2022-06-23 | Johnson & Johnson Vision Care, Inc. | Photostable mimics of macular pigment |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012271357A1 (en) | 2011-06-16 | 2013-05-02 | Ionis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
| NZ703495A (en) * | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| JP6084292B2 (ja) | 2013-07-18 | 2017-02-22 | 大鵬薬品工業株式会社 | Fgfr阻害剤耐性癌の治療薬 |
| SG11201602069WA (en) | 2013-10-18 | 2016-04-28 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| PT3395814T (pt) | 2013-10-25 | 2022-07-27 | Blueprint Medicines Corp | Inibidores do recetor do fator de crescimento de fibroblastos |
| CN105683188B (zh) | 2013-10-25 | 2018-02-09 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| WO2015108992A1 (en) * | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| JP6655559B2 (ja) | 2014-06-24 | 2020-02-26 | コベストロ、ドイチュラント、アクチエンゲゼルシャフトCovestro Deutschland Ag | ジフェニルメタン系ジアミンおよびポリアミンの製造方法 |
| WO2016064960A1 (en) * | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| EP3029864B1 (en) | 2014-12-01 | 2020-11-18 | Harman Becker Automotive Systems GmbH | Fast representation of station information in a fm receiver using a single tuner |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) * | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN105906630B (zh) | 2015-04-06 | 2018-10-23 | 四川百利药业有限责任公司 | 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物 |
| WO2016164703A1 (en) | 2015-04-09 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Fgfr4 inhibitors |
| CN107286130A (zh) * | 2016-04-13 | 2017-10-24 | 成都融科博海科技有限公司 | 一种激酶选择性抑制剂 |
| RU2747260C2 (ru) * | 2016-12-19 | 2021-04-29 | Аббиско Тхерапеутицс Цо., Лтд. | Ингибитор рфрф4, способ его получения и его фармацевтическое применение |
| CN110997637B (zh) * | 2017-09-05 | 2022-09-27 | 保仕健生物科技(上海)有限公司 | 芳香类衍生物、其制备方法及其在医药上的应用 |
| CN109224235B (zh) | 2018-10-23 | 2020-05-19 | 孙喜家 | 一种双腔管 |
| CN109331654A (zh) | 2018-10-26 | 2019-02-15 | 高邮高和光电器材有限公司 | 一种有机废气光催化氧化装置 |
-
2019
- 2019-03-05 WO PCT/CN2019/076926 patent/WO2020177067A1/en not_active Ceased
-
2020
- 2020-02-19 EP EP20767365.8A patent/EP3935048A4/en not_active Withdrawn
- 2020-02-19 WO PCT/CN2020/075849 patent/WO2020177534A1/en not_active Ceased
- 2020-02-19 CN CN202080000743.2A patent/CN111902400B/zh active Active
- 2020-02-19 KR KR1020217031713A patent/KR20210135558A/ko not_active Ceased
- 2020-02-19 CA CA3132405A patent/CA3132405A1/en active Pending
- 2020-02-19 JP JP2021552591A patent/JP7470708B2/ja active Active
- 2020-02-19 US US17/436,476 patent/US11976058B2/en active Active
- 2020-02-19 PH PH1/2021/552133A patent/PH12021552133A1/en unknown
- 2020-02-19 SG SG11202109522VA patent/SG11202109522VA/en unknown
- 2020-03-05 TW TW109107205A patent/TWI860334B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202109522VA (en) | 2021-09-29 |
| WO2020177067A1 (en) | 2020-09-10 |
| US20220169634A1 (en) | 2022-06-02 |
| CN111902400A (zh) | 2020-11-06 |
| US11976058B2 (en) | 2024-05-07 |
| WO2020177534A1 (en) | 2020-09-10 |
| CA3132405A1 (en) | 2020-09-10 |
| EP3935048A1 (en) | 2022-01-12 |
| EP3935048A4 (en) | 2022-11-09 |
| KR20210135558A (ko) | 2021-11-15 |
| TWI860334B (zh) | 2024-11-01 |
| JP2022522890A (ja) | 2022-04-20 |
| TW202100514A (zh) | 2021-01-01 |
| CN111902400B (zh) | 2024-08-30 |
| JP7470708B2 (ja) | 2024-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022550399A1 (en) | MTA-Cooperative PRMT5 Inhibitors | |
| CR20220070A (es) | Inhibidores de parp1 | |
| MX2025003876A (es) | Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina | |
| WO2020106642A8 (en) | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin | |
| MY209609A (en) | Immunomodulators, compositions and methods thereof | |
| PH12021550187A1 (en) | Pyrrolopyrimidine itk inhibitors | |
| ZA201904234B (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| EP4374858A3 (en) | Benzimidazolone derived inhibitors of bcl6 | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| GEAP202014820A (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| PH12021500034A1 (en) | Compounds useful in hiv therapy | |
| AU2020258568A8 (en) | CD73 inhibitors | |
| EP4442318A3 (en) | Heterocyclic inhibitors of mct4 | |
| MY209035A (en) | Tricyclic compounds and their use | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MY202884A (en) | Compounds useful in hiv therapy | |
| PH12017502112B1 (en) | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors | |
| MX2020004981A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
| MX2021015333A (es) | Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| AU2020378127A8 (en) | Compounds as CD73 inhibitors |